Key result
Sitaxsentan improves exercise capacity, functional class, and hemodynamics versus placebo in PAH.
Why the study?
Pulmonary arterial hypertension is a progressive, life-threatening condition requiring effective and safe treatments such as selective endothelin-A receptor antagonists.
Does sitaxsentan improve exercise capacity and hemodynamics in adult patients with pulmonary arterial hypertension?
Does sitaxsentan improve exercise capacity and hemodynamics in adult patients with pulmonary arterial hypertension?
Sitaxsentan is an effective and well-tolerated endothelin-A receptor antagonist that improves exercise capacity and hemodynamics in PAH, though it requires warfarin dose adjustment.
Sitaxsentan improves walk distance and hemodynamics in PAH; extends RCT data but leaves comparative long-term outcomes open.
Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition. Sitaxsentan, a selective endothelin-A receptor antagonist, is an effective, safe and well-tolerated endothelin receptor antagonist for the treatment of PAH in adult patients. Multi-center, randomized, placebo-controlled clinical trials have demonstrated that sitaxsentan has beneficial effects on exercise capacity (i.e., 6-min walk distance), functional class and hemodynamic parameters in PAH patients. Sitaxsentan has a low incidence of acute hepatotoxicity. Patients on concomitant warfarin require a decrease in warfarin dose to maintain a therapeutic international normalized ratio. The demonstration of clinical efficacy and low incidence of acute hepatotoxicity support the potential use of sitaxsentan for the treatment of PAH.
No takes yet. Share an insight, caveat, or question.
Robyn J. Barst (2006) conducted a review in Pulmonary arterial hypertension (PAH). Sitaxsentan vs. Placebo was evaluated on Exercise capacity (6-min walk distance), functional class and hemodynamic parameters. Sitaxsentan demonstrated beneficial effects on exercise capacity, functional class, and hemodynamic parameters in adult patients with pulmonary arterial hypertension.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: